array(3) { ["company_details"]=> array(13) { ["name"]=> string(26) "Bio-RAD Laboratories, Inc." ["slug"]=> string(33) "001cd-us-bio-rad-laboratories-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/9d1c28c2-1b47-4093-8ed2-5151f3fe7920" ["description"]=> string(867) "Since Bio-Rad was founded 70 years ago, we have continued to provide the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. Throughout our existence, we have built long-lasting customer relationships that help advance our research and development efforts in the introduction of new products and solutions. Today, Bio-Rad is a global leader, with a team of over 8,000 employees and a global network of operations that serves our life science research and clinical diagnostics customers, advancing science and saving lives, together. #Biotechnology #Biotech #STEM #Research #Biology #Chemistry #Science #PeerReviewed #Diabetes #CancerResearch #HIVResearch #Laboratory #BioRad #Cancer #DiabetesResearch #AIDSResearch #ClinicalDiagnostics" ["address_street"]=> string(20) "1000 Alfred Nobel Dr" ["address_place"]=> string(8) "Hercules" ["address_region"]=> string(10) "California" ["founding_date"]=> string(10) "1952-02-08" ["website_domain"]=> string(11) "bio-rad.com" ["website_url"]=> string(23) "https://www.bio-rad.com" ["industry_codes"]=> array(3) { [0]=> string(42) "In Vitro and In Vivo Diagnostic Substances" [1]=> string(33) "Laboratory Analytical Instruments" [2]=> string(47) "Electromedical and Electrotherapeutic Apparatus" } ["employee_count"]=> int(7900) ["article_count"]=> int(659) } ["articles"]=> array(2) { [0]=> array(7) { ["title_en"]=> string(56) "Bio-Rad Attorney Wins $11 Million in Whistleblower Trial" ["snippet_en"]=> string(226) "A federal jury Monday awarded the former general counsel of Bio-Rad Laboratories $8 million in back pay and damages — which will increase to $11 million — for whistleblower retaliation involving potential bribery in China." ["url"]=> string(86) "https://www.courthousenews.com/biorad-attorney-wins-11-million-in-whistleblower-trial/" ["image_url"]=> NULL ["source"]=> string(18) "courthousenews.com" ["publication_date"]=> string(10) "2023-11-10" ["categories"]=> array(11) { [0]=> string(19) "Economic Conditions" [1]=> string(24) "Quarterly/Annual Figures" [2]=> string(7) "Scandal" [3]=> string(8) "Verdicts" [4]=> string(7) "Bribery" [5]=> string(20) "Corporate Governance" [6]=> string(16) "Case Settlements" [7]=> string(10) "Misconduct" [8]=> string(5) "Legal" [9]=> string(15) "Business Ethics" [10]=> string(15) "Corporate Fines" } } [1]=> array(7) { ["title_en"]=> string(145) "Ninth Circuit Holds That Statutes Do Not Constitute “Rules or Regulations of the SEC” for Purposes of Sarbanes-Oxley Act Whistleblower Claims" ["snippet_en"]=> string(164) "Ninth cir holds that rules like FCPA don't quantify as “Rules or Regulations of the SEC” when determining whistleblower SOX violations when filing with the SEC." ["url"]=> string(117) "https://www.natlawreview.com/article/ninth-circuit-holds-statutes-do-not-constitute-rules-or-regulations-sec-purposes" ["image_url"]=> string(78) "https://images.businessradar.com/articles/61ce51e5-9e91-41c7-9d47-88971d8afe9a" ["source"]=> string(16) "natlawreview.com" ["publication_date"]=> string(10) "2021-10-06" ["categories"]=> array(6) { [0]=> string(15) "Supply & Demand" [1]=> string(7) "Scandal" [2]=> string(11) "Air Quality" [3]=> string(5) "Legal" [4]=> string(10) "Litigation" [5]=> string(46) "Management of Legal and Regulatory Environment" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(66) } [1]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(51) } [2]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(31) } [3]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(28) } [4]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(26) } [5]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(24) } [6]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(23) } [7]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(20) } [8]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(19) } [9]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(19) } [10]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(19) } [11]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(18) } [12]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(14) } [13]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(14) } [14]=> array(2) { ["name"]=> string(18) "Ecological Impacts" ["count"]=> int(13) } [15]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(13) } [16]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(9) } [17]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(9) } [18]=> array(2) { ["name"]=> string(10) "New Market" ["count"]=> int(9) } [19]=> array(2) { ["name"]=> string(11) "Regulations" ["count"]=> int(9) } [20]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(8) } [21]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(7) } [22]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(7) } [23]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(7) } [24]=> array(2) { ["name"]=> string(6) "Merger" ["count"]=> int(7) } [25]=> array(2) { ["name"]=> string(16) "Case Settlements" ["count"]=> int(6) } [26]=> array(2) { ["name"]=> string(13) "Credit Rating" ["count"]=> int(5) } [27]=> array(2) { ["name"]=> string(15) "Business Ethics" ["count"]=> int(5) } [28]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(5) } [29]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(5) } } } 001cd-us-bio-rad-laboratories-inc